Liraglutide: FDA records on compounded and unapproved products
Has FDA taken action on compounded liraglutide?
Yes. As of Nov 15, 2026, FDA has issued 3 warning letters to 3 companies whose text names liraglutide, the latest dated Jun 8, 2026, and openFDA lists no recall report naming it. FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances (statement dated Apr 30, 2026).
As of Nov 15, 2026, FDA’s drug shortage data lists 9 presentations of liraglutide with status “Current.”
What FDA has stated, by date
- Feb 21, 2025: FDA determined that the shortage of semaglutide injection products is resolved. FDA said it did not intend to take action, for violations that depend on semaglutide being on the shortage list, against 503A pharmacies and physicians until April 22, 2025, or 503B outsourcing facilities until May 22, 2025 (or a pending court decision, whichever was later). The same update listed liraglutide injection as in shortage. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- May 1, 2026: The proposal was published in the Federal Register (Docket No. FDA-2018-N-3240, 91 FR 23431) with comments due June 30, 2026. Source: Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Jun 26, 2026: FDA extended to July 30, 2026 the comment period on its proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. Source: Federal Register, June 26, 2026: Extension of Comment Period
FDA drug shortage status
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Hikma Pharmaceuticals USA, Inc. | Current | Oct 14, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Meitheal Pharmaceuticals, Inc. | Current | Aug 27, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | May 14, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Novo Nordisk, Inc. | Current | Sep 22, 2026 |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Novo Nordisk, Inc. | Current | Sep 22, 2026 |
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Novo Nordisk, Inc. | Current | Sep 22, 2026 |
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Novo Nordisk, Inc. | To Be Discontinued | Aug 25, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Novo Nordisk, Inc. | Current | Sep 22, 2026 |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Novo Nordisk, Inc. | Current | Sep 22, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Meitheal Pharmaceuticals, Inc. | Current | Aug 27, 2026 |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Hikma Pharmaceuticals USA, Inc. | Current | Oct 14, 2026 |
Shortage history, by date
| FDA’s words or record | Source | ||
|---|---|---|---|
| Jul 18, 2023 | Listed | FDA’s shortage data posts Liraglutide Injection (Liraglutide, Victoza, Saxenda) with status “Current,” first posted Jul 18, 2023: 9 presentations. | FDA drug shortage data, via openFDA drug shortages endpoint |
| Feb 21, 2025 | Status statement | “Liraglutide injection : In shortage. Manufacturer has reported two presentations are available, and three have limited availability.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 14, 2026 | To Be Discontinued | FDA’s shortage data posts Liraglutide Injection (Liraglutide) with status “To Be Discontinued,” first posted May 14, 2026: 1 presentation. | FDA drug shortage data, via openFDA drug shortages endpoint |
| Aug 25, 2026 | To Be Discontinued | FDA’s shortage data posts Liraglutide Injection (Saxenda) with status “To Be Discontinued,” first posted Aug 25, 2026: 1 presentation. | FDA drug shortage data, via openFDA drug shortages endpoint |
All GLP-1 drugs on one timeline: shortage history.
FDA adverse event reports (FAERS) listing liraglutide
openFDA’s copy of FDA’s adverse event database holds 40,829 reports that list liraglutide, received from Feb 13, 2004 through Sep 30, 2026. 21,974 (54%) are marked serious by the reporter, including 1,668 that list death as an outcome. No report names a compounded or combination liraglutide product in the product fields, under the rule this index uses. These are unverified reports and do not show that the drug caused any event.
FAERS reports are sent to FDA by drug makers, health professionals and the public. FDA does not verify them, a report does not show that the drug caused the event, and the same event can be reported more than once. Counts reflect how often events were reported, not how often they happen or how risky a drug is. Nothing here is medical advice. Report an error or add a company response.
Reports by year FDA received them
| 2004 | 4 |
| 2007 | 7 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 47 |
| 2011 | 120 |
| 2012 | 1,379 |
| 2013 | 837 |
| 2014 | 1,418 |
| 2015 | 5,182 |
| 2016 | 4,708 |
| 2017 | 3,612 |
| 2018 | 4,709 |
| 2019 | 3,273 |
| 2020 | 2,921 |
| 2021 | 2,526 |
| 2022 | 2,034 |
| 2023 | 2,067 |
| 2024 | 1,850 |
| 2025 | 2,215 |
| 2026 | 1,911 |
Reaction terms listed most often
| Nausea | 5,031 | 12.3% |
| Blood glucose increased | 2,958 | 7.2% |
| Vomiting | 2,836 | 6.9% |
| Diarrhoea | 2,599 | 6.4% |
| Off label use | 1,889 | 4.6% |
| Pancreatitis | 1,737 | 4.3% |
| Headache | 1,475 | 3.6% |
| Fatigue | 1,431 | 3.5% |
| Decreased appetite | 1,416 | 3.5% |
| Drug ineffective | 1,416 | 3.5% |
A report can list several reaction terms. Terms such as “Off label use” or “Incorrect dose administered” describe how the drug was used, not a bodily reaction.
Reports naming a compounded or combination liraglutide product
In openFDA’s public copy of FDA’s adverse event data, checked Nov 15, 2026 and covering reports received through Sep 30, 2026, no report listing liraglutide has product text that names a compounded or combination product, under the rule described below. That is not evidence that no such events were reported: the public data has no compounded flag and no narrative.
A report is counted as naming a compounded product only when one drug entry in it names the drug and that same entry either uses the word “compounded”, “compounding” or “compound” in its product name or dosage text, or lists the drug together with cyanocobalamin, methylcobalamin, pyridoxine, glycine, levocarnitine, carnitine, niacinamide or vitamin B12 or B6 in one product name, a combination no FDA-approved product of these drugs contains. openFDA’s public data has no field that marks a product as compounded and leaves out the report narrative, so this finds only reports whose product text shows it. FDA’s own counts for compounded semaglutide and tirzepatide, from its full internal data, are higher.
Active ingredient (API) imports: FDA import alert and refusal records
FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has 10 entries naming liraglutide, in China (6), India (2), Denmark (1) and Italy (1); FDA redacts the firm names. FDA’s import refusal records list 4 refused shipment lines whose product code names liraglutide, from Nov 26, 2025 to Sep 18, 2026, most often from Mexico (2), Canada (1) and United States (1); 0 carry an API or powder product code listed on the alert.
Import Alert 66-80 Green List entries naming liraglutide
| Product codes and drugs listed | |||
|---|---|---|---|
| 5 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 7 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 8 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 9 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 10 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 13 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 15 | Redacted by FDA | DENMARK | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) |
| 16 | Redacted by FDA | INDIA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 18 | Redacted by FDA | INDIA | 61P[][]76 Liraglutide (Anti-Diabetic) |
| 21 | Redacted by FDA | ITALY | 61P[][]76 Liraglutide (Anti-Diabetic) |
Refused liraglutide lines by country and form
| Mexico | 2 |
| Canada | 1 |
| United States | 1 |
| Code not listed on Import Alert 66-80 | 4 |
Most recent refused liraglutide lines
| Shipment ID | |||||
|---|---|---|---|---|---|
| Sep 18, 2026 | Name not shown | United States | 61PDY76 LIRAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9731409-8/10001/1 |
| Jan 9, 2026 | NOVO NORDISK SERV PROF S A DE CV | Mexico | 61PDY76 LIRAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9134272-3/20003/1 |
| Dec 19, 2025 | NOVO NORDISK SERV PROF S A DE CV | Mexico | 61PDY76 LIRAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9048333-8/10003/1 |
| Nov 26, 2025 | Novo Nordisk | Canada | 61PCB76 LIRAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 799-0033969-1/20003/1 |
All firms and countries: Firms on GLP-1 import records.
FDA NDC Directory listings
FDA’s NDC Directory files read Nov 15, 2026 carry 66 listings naming liraglutide: BULK INGREDIENT (34); ANDA (15); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (5); NDA (5); OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4); NDA AUTHORIZED GENERIC (2); BLA (1). Outsourcing facility listings: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA? Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”
Medicare and Medicaid spending on liraglutide
Medicare Part D spent $329.0 million on liraglutide brands in 2024 (Victoza 3-Pak $203.1 million, Victoza 2-Pak $77.8 million, Liraglutide $48.1 million), before manufacturer rebates, according to CMS. Pharmacies were reimbursed $145.9 million for liraglutide products paid through Medicaid nationwide in 2025, across 262,711 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states.
Medicare Part D, by brand and year
| Victoza 3-Pak | Liraglutide | $1,545,815,415 | $1,422,292,583 | $1,238,594,872 | $1,004,635,145 | $203,063,050 |
| Victoza 2-Pak | Liraglutide | $349,476,159 | $334,897,957 | $319,205,509 | $317,213,565 | $77,832,721 |
| Liraglutide | Liraglutide | No data | No data | No data | No data | $48,095,824 |
Medicaid, nationwide, by year
| 2020 | $567,508,684 |
| 2021 | $680,639,494 |
| 2022 | $722,777,322 |
| 2023 | $722,050,605 |
| 2024 | $294,458,438 |
| 2025 | $145,922,324 |
| 2026 (Q1) | at least $24,183,285 |
Xultophy (insulin degludec and liraglutide) is counted separately, as a combination product, on the spending page.
Figures are before manufacturer rebates, as CMS reports them. Every GLP-1 drug, CMS’s caveats and each state: Medicare and Medicaid spending on GLP-1 drugs.
FDA warning letters naming liraglutide
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Jun 8, 2026 | Momentum Health 360 dba Momentum Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Kare Solutions, LLC dba Zappy | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Levity Inc. dba Levity | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recalls naming liraglutide
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA Adverse Event Reporting System (FAERS), via openFDA drug event endpoint
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Federal Register, June 26, 2026: Extension of Comment Period
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.